A clinical trial sponsored by the National Institutes of Health (NIH) has demonstrated that acetaminophen shows promise in preventing organ injury and acute respiratory distress syndrome (ARDS) in patients with sepsis. The Phase 2b randomized trial (RCT), presented at the ATS 204 conference and published in JAMA, found that only 2.2% of patients in the acetaminophen arm developed ARDS compared to 8.5% in the placebo arm. The study also reported no significant differences in liver enzymes, hypotension, or fluid balance between the treatment groups, indicating the safety of acetaminophen in this context.
A clinical trial sponsored by the National Institutes of Health (NIH) has shown that acetaminophen reduces the risk of sepsis patients experiencing organ damage or developing acute respiratory distress syndrome. Learn more: https://t.co/0bDfgoEbp4 https://t.co/maGR7b4nSB
“Some of the trial's secondary outcomes did reach statistical significance. For example, researchers found that only 2.2% of patients in the acetaminophen arm developed acute respiratory distress syndrome (ARDS) compared with 8.5% in the placebo arm” https://t.co/syopKvHMXQ
Acetaminophen for Prevention & Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis:RCT: Acetaminophen was safe with no diff in liver enzymes, hypotension, fluid balance between treatment arms. https://t.co/E6OPwrpyTx
Phase 2b Randomized Trial of Acetaminophen for Prevention & Treatment of Organ Dysfunction in Critically Ill Sepsis Patients, presented at #ATS204, is online from JAMA https://t.co/9g1fMBHh6c https://t.co/cDV6S8aBzm
Acetaminophen shows promise in warding off #acuteRespiratoryDistressSyndrome, organ injury in patients with #sepsis @nih_nhlbi @JAMA_current https://t.co/roZyyliKfh